Literature DB >> 20097372

Differential expression of hepatic fibrosis mediators in sick and spontaneously recovered mice with experimental biliary atresia.

Evan P Nadler1, Xiaolu Li, Emeka Onyedika, M Alba Greco.   

Abstract

BACKGROUND: Hepatic fibrosis leading to cirrhosis is the major morbidity in patients with biliary atresia (BA). This fibrosis is due to an imbalance in extracellular matrix (ECM) breakdown and deposition. We have previously demonstrated increased mRNA expression for inhibitors of ECM breakdown without increased expression for mediators of ECM deposition in our animal model of BA by d 14. However, only a mild degree of hepatic fibrosis was seen at this time. We hypothesized that expression patterns for these proteins may change once more significant fibrosis had been established, and added resuscitation to the model to improve survival. Interestingly, we found that some mice spontaneously recovered at later time points with resuscitation, and thus compared expression for inhibitors of ECM breakdown and deposition in sick and recovered mice to determine the differences.
METHODS: Newborn Balb/c mice received an intraperitoneal injection 1.0 x 10(6) fluorescence forming units of rhesus rotavirus 24h after birth. Mice were monitored daily for weight gain, development of jaundice, acholic stools, and bilirubinuria. Fifty muL/g of 5% dextrose in normal saline were subcutaneously injected daily to each mouse starting on d 7 until sacrifice. Mice that survived past d 14 were sacrificed at d 21 after saline or RRV infection. Livers were then harvested post-injection d 21 for histologic and immunohistochemical analysis. RNA expression of known mediators of fibrosis was evaluated using quantitative real-time PCR. Protein expression was assessed using ELISA. Weights and normally distributed data were compared using Student's t test. Histologic findings were compared using Fisher's exact test. Comparisons of gene expression and skewed data were performed by the Mann-Whitney U test. Statistical significance was assigned to any P value less than 0.05.
RESULTS: Daily resuscitation resulted in a 35% (24/68) survival rate to d 21 in our model. Mice that recovered were significantly heavier than those that remained ill on d 14 (6.15 +/- 1.16 versus 4.94 +/- 0.82, P = 0.02) and 21 (7.31 +/- 1.41 versus 4.14 +/- 0.53, P < 0.001) despite the fact that there was no difference between the groups with respect to weight on d 7 (4.29 +/- 0.90 versus 3.89 +/- 0.81, P = 0.32). We found that all (10/10) animals that displayed clinical signs of biliary atresia on d 21 had moderate or severe histologic findings, while only one (1/9) of the recovered animals had liver abnormalities at sacrifice (P < 0.001 versus sick group). We also found that the sick mice had statistically significant median fold-increases of mRNA expression for TIMP-1 (31.9 versus 9.1, P = 0.041), TIMP-4 (88.1 versus 1.8, P = 0.022), and MMP-7 (51.8 versus 11.9, P = 0.006) compared with those that recovered. There was a trend toward decreased mRNA expression for PAI-1, which did not reach statistical significance (median 27.7 versus 2.19, P = 0.066). Increased protein expression for TIMP-1 and PAI-1 were also found in the sick group. The mRNA expression for the fibrillar collagens, fibronectin-1, connective tissue growth factor, snail-1, TIMP-2 and -3, and MMP-2 and MMP-9 was not different in the sick and recovered groups 21 d after RRV infection, and was not elevated from baseline gene expression.
CONCLUSIONS: With resuscitation added to the animal model of BA, some mice spontaneously recover while others progress to more significant hepatic fibrosis. Mice with hepatic fibrosis have a continued increase in mRNA expression of TIMP-1, TIMP-4, and MMP-7, with a trend toward increased mRNA expression of PAI-1 on d 21. Protein levels for TIMP-1 and PAI-1 were also increased in the sick mice. Recovered mice display mild to no hepatic parenchymal disease and a normal pattern of mRNA expression for the mediators of fibrosis tested. No increase in mRNA expression for the mediators of ECM deposition was found in either group. These data further support the notion that inhibition of ECM breakdown alone is sufficient to induce hepatic fibrosis. Modulation of this process may be a putative target for preventing liver injury in patients with BA.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20097372      PMCID: PMC2844460          DOI: 10.1016/j.jss.2009.10.038

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  21 in total

1.  Transcriptional profiling after bile duct ligation identifies PAI-1 as a contributor to cholestatic injury in mice.

Authors:  Hongtao Wang; Bhupinder P S Vohra; Yan Zhang; Robert O Heuckeroth
Journal:  Hepatology       Date:  2005-11       Impact factor: 17.425

2.  In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis.

Authors:  J George; D Roulot; V E Koteliansky; D M Bissell
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

3.  Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat.

Authors:  Z Qi; N Atsuchi; A Ooshima; A Takeshita; H Ueno
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

4.  Evaluation of matrix metalloproteinases and their endogenous tissue inhibitors in biliary atresia-associated liver fibrosis.

Authors:  Chih-Sung Hsieh; Jiin-Haur Chuang; Chao-Cheng Huang; Ming-Huei Chou; Chia-Lin Wu; Shin-Yi Lee; Chao-Long Chen
Journal:  J Pediatr Surg       Date:  2005-10       Impact factor: 2.545

5.  New aspects in a murine model for extrahepatic biliary atresia.

Authors:  C Petersen; D Biermanns; M Kuske; K Schäkel; L Meyer-Junghänel; H Mildenberger
Journal:  J Pediatr Surg       Date:  1997-08       Impact factor: 2.545

Review 6.  Matrix metalloproteinase knockout studies and the potential use of matrix metalloproteinase inhibitors in the rheumatic diseases.

Authors:  Jennifer M Milner; Tim E Cawston
Journal:  Curr Drug Targets Inflamm Allergy       Date:  2005-06

7.  Contribution of hepatic parenchymal and nonparenchymal cells to hepatic fibrogenesis in biliary atresia.

Authors:  G A Ramm; V G Nair; K R Bridle; R W Shepherd; D H Crawford
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

8.  Integrin alphavbeta6 and mediators of extracellular matrix deposition are up-regulated in experimental biliary atresia.

Authors:  Evan P Nadler; Danielle Patterson; Shelia Violette; Paul Weinreb; Michael Lewis; Margaret S Magid; M Alba Greco
Journal:  J Surg Res       Date:  2008-06-20       Impact factor: 2.192

9.  Identification of transforming growth factors actively transcribed during the progress of liver fibrosis in biliary atresia.

Authors:  Shin-Ye Lee; Jiin-Haur Chuang; Chao-Cheng Huang; Ming-Huei Chou; Chia-Ling Wu; Ching-Mei Chen; Chie-Song Hsieh; Chao-Long Chen
Journal:  J Pediatr Surg       Date:  2004-05       Impact factor: 2.545

10.  Obstruction of extrahepatic bile ducts by lymphocytes is regulated by IFN-gamma in experimental biliary atresia.

Authors:  Pranavkumar Shivakumar; Kathleen M Campbell; Gregg E Sabla; Alexander Miethke; Greg Tiao; Monica M McNeal; Richard L Ward; Jorge A Bezerra
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

View more
  7 in total

1.  Dysregulation of upstream and downstream transforming growth factor-β transcripts in livers of children with biliary atresia and fibrogenic gene signatures.

Authors:  Tatiana Iordanskaia; Monica J Hubal; Emily Koeck; Christopher Rossi; Kathleen Schwarz; Evan P Nadler
Journal:  J Pediatr Surg       Date:  2013-10       Impact factor: 2.545

Review 2.  Recent developments in diagnostics and treatment of neonatal cholestasis.

Authors:  Amy G Feldman; Ronald J Sokol
Journal:  Semin Pediatr Surg       Date:  2020-07-23       Impact factor: 2.754

Review 3.  The Sea Lamprey as an Etiological Model for Biliary Atresia.

Authors:  Yu-Wen Chung-Davidson; Chu-Yin Yeh; Weiming Li
Journal:  Biomed Res Int       Date:  2015-05-26       Impact factor: 3.411

Review 4.  Aetiology of biliary atresia: what is actually known?

Authors:  Claus Petersen; Mark Davenport
Journal:  Orphanet J Rare Dis       Date:  2013-08-29       Impact factor: 4.123

Review 5.  Role of viruses in biliary atresia: news from mice and men.

Authors:  Claus Petersen; Omid Madadi-Sanjani
Journal:  Innov Surg Sci       Date:  2018-04-04

6.  Serum proteome profiling identifies novel and powerful markers of cystic fibrosis liver disease.

Authors:  Timo Rath; Lisa Hage; Marion Kügler; Katrin Menendez Menendez; Reinhart Zachoval; Lutz Naehrlich; Richard Schulz; Martin Roderfeld; Elke Roeb
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240

7.  Increased MMP-7 expression in biliary epithelium and serum underpins native liver fibrosis after successful portoenterostomy in biliary atresia.

Authors:  Anna Kerola; Hanna Lampela; Jouko Lohi; Päivi Heikkilä; Annika Mutanen; Jaana Hagström; Taina Tervahartiala; Timo Sorsa; Caj Haglund; Hannu Jalanko; Mikko P Pakarinen
Journal:  J Pathol Clin Res       Date:  2016-05-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.